On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...

Updates on ASH Clinical Practice Guidelines in Development

In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish evidence-based clinical practice guidelines to help practicing hematologists and...

Time-Limited Acalabrutinib Combination Has “Encouraging” Response Rates in Previously Untreated Chronic Lymphocytic Leukemia

Watch our interview with Benjamin Lampson, MD. Preliminary results from a trial presented at the 2019 ASH Annual Meeting suggest that time-limited frontline therapy for...

Adding Navitoclax to Ruxolitinib in Ruxolitinib-Refractory Myelofibrosis Leads to Improvements in Spleen Volume, Symptom...

Watch our interview with Jacqueline Garcia, MD. More than one-third of patients with myelofibrosis (MF) who had not responded adequately to monotherapy with the FDA-approved...

KTE-X19: A CAR T-Cell Option for Mantle Cell Lymphoma?

According to results from the ZUMA-2 trial presented at the 2019 ASH Annual Meeting, 93% of patients with relapsed/refractory mantle cell lymphoma (MCL) responded...

Early-Phase Trial Shows Mosunetuzumab Induces Durable Complete Remissions in Patients With B-Cell Non-Hodgkin...

Watch our interview with Stephen J. Schuster, MD. The bispecific monoclonal antibody mosunetuzumab, which binds to CD3 and CD20, led to durable responses in patients...

Early-Phase Trial Suggests Bispecific Antibody CC-93269 Has Activity in Relapsed/Refractory Multiple Myeloma

Watch our interview with Luciano J. Costa, MD, PhD. CC-93269, a bispecific antibody that binds B-cell maturation antigen (BCMA) on malignant plasma cells and CD3...

Are Clinical Trial Exclusion Criteria for Patients With AML Too Strict?

Watch our interview with Abby Statler, MD, MPH. In a study presented at the 2019 ASH Annual Meeting, researchers found that certain comorbidities in patients...

Daratumumab, Carfilzomib, and Dexamethasone Combination Improves PFS in Patients with Relapsed/Refractory Multiple Myeloma

Adding daratumumab to a combination of carfilzomib and dexamethasone (KdD) led to a 37% improvement in progression-free survival (PFS), compared with carfilzomib and dexamethasone...

QUAZAR: Oral Azacitidine Maintenance Improves Survival in Transplant-Ineligible AML

According to research presented as a late-breaking abstract at the 2019 ASH Annual Meeting, treatment with CC-486, an oral formulation of the hypomethylating agent...
Advertisement

Current Issue

January 2020 Annual Meeting Edition

This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.